{"nctId":"NCT01764386","briefTitle":"Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects","startDateStruct":{"date":"2013-02"},"conditions":["Obesity","Overweight"],"count":242,"armGroups":[{"label":"NB + CLI","type":"EXPERIMENTAL","interventionNames":["Drug: NB","Behavioral: CLI"]},{"label":"Usual Care","type":"OTHER","interventionNames":["Behavioral: Usual Care"]}],"interventions":[{"name":"NB","otherNames":[]},{"name":"CLI","otherNames":[]},{"name":"Usual Care","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female or male, 18 to 60 years old\n* Body mass index (BMI) ≥30 kg/m2 and ≤45 kg/m2 for subjects with uncomplicated obesity, or BMI ≥27 kg/m2 and ≤45 kg/m2 for subjects with dyslipidemia and/or controlled hypertension\n\nExclusion Criteria:\n\n* History of type 1 or type 2 diabetes mellitus diagnosis\n* Myocardial infarction within 6 months prior to screening\n* Angina pectoris Grade III or IV as per the Canadian Cardiovascular Society grading scheme\n* Clinical history of large vessel cortical strokes, including ischemic and hemorrhagic strokes (i.e., transient ischemic attack is not exclusionary)\n* History (within the last 20 years) of seizures, cranial trauma, bulimia, anorexia nervosa, or other conditions that predispose subjects to seizures\n* Past or planned surgical or device intervention (e.g., gastric banding) for obesity\n* Chronic use or positive screen for opioids\n* Regular use of tobacco products","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in Body Weight From Baseline (Day 1) to Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.46","spread":"0.54"},{"groupId":"OG001","value":"-0.94","spread":"0.49"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving a Loss of at Least 5% of Baseline Body Weight at Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.5","spread":null},{"groupId":"OG001","value":"12.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving a Loss of at Least 10% of Baseline Body Weight at Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.3","spread":null},{"groupId":"OG001","value":"3.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving a Loss of at Least 15% of Baseline Body Weight at Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Body Weight From Baseline to Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.7","spread":"0.56"},{"groupId":"OG001","value":"-1.0","spread":"0.51"}]}]}]},{"type":"SECONDARY","title":"Change in Waist Circumference From Baseline to Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.96","spread":"0.705"},{"groupId":"OG001","value":"-1.64","spread":"0.659"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Triglycerides From Baseline to Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.6","spread":"4.96"},{"groupId":"OG001","value":"2.8","spread":"4.63"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Low-density Lipoprotein Cholesterol From Baseline to Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"2.20"},{"groupId":"OG001","value":"-1.9","spread":"2.11"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting High-density Lipoprotein Cholesterol From Baseline to Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"0.77"},{"groupId":"OG001","value":"0.1","spread":"0.73"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure From Baseline to Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"1.10"},{"groupId":"OG001","value":"-2.8","spread":"1.02"}]}]}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure From Baseline to Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"0.83"},{"groupId":"OG001","value":"-1.3","spread":"0.77"}]}]}]},{"type":"SECONDARY","title":"Change in Heart Rate From Baseline to Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"0.88"},{"groupId":"OG001","value":"-0.3","spread":"0.82"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose From Baseline to Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"1.04"},{"groupId":"OG001","value":"1.6","spread":"0.96"}]}]}]},{"type":"SECONDARY","title":"Change Fasting Insulin From Baseline to Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.5","spread":"0.79"},{"groupId":"OG001","value":"-3.4","spread":"0.76"}]}]}]},{"type":"SECONDARY","title":"Change in Homeostasis Model Assessment-insulin Resistance (HOMA-IR) From Baseline to Week 26","description":"HOMA-IR is an insulin sensitivity index that is calculated as HOMA-IR = (Glucose \\* Insulin) / 405, where glucose is in mass units (mg/dL) and insulin is in µIU/mL. Higher values indicate lower insulin sensitivity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"0.20"},{"groupId":"OG001","value":"-0.8","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Change in Patient-reported Binge Eating Scale (BES) Total Scores From Baseline to Week 26","description":"The BES is a 16-item questionnaire that identifies different levels of binge-eating severity, with total scores ranging between 0-46. BES scores were categorized as follows: None = Scores ≤17 indicated no significant binge eating, Moderate = scores from 18 to 26 (inclusive), Severe = scores ≥27 indicated severe levels of binge eating.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.8","spread":"0.72"},{"groupId":"OG001","value":"1.1","spread":"0.67"}]}]}]},{"type":"SECONDARY","title":"Change in Patient-reported Arizona Sexual Experiences Scale (ASEX) Total Scores From Baseline to Week 26","description":"Arizona Sexual Experiences (ASEX) scale is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30, with the higher scores indicating more sexual dysfunction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"0.36"},{"groupId":"OG001","value":"-0.1","spread":"0.34"}]}]}]},{"type":"SECONDARY","title":"Change in Patient-reported Impact of Weight on Quality of Life-Lite Questionnaire (IWQOL-Lite) Total Score From Baseline to Week 26","description":"Impact of Weight on Quality of Life-Lite Questionnaire (IWQOL-Lite) is a self-reported assessment of perceived effect of weight on quality of life. It consists of 31 items organized in 5 domains (physical function, self-esteem, sexual life, public distress and work). IWQOL-Lite total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4","spread":"1.50"},{"groupId":"OG001","value":"-1.0","spread":"1.41"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":153},"commonTop":["Nausea","Anxiety","Headache","Insomnia","Dizziness"]}}}